EFPIA：2025年未来保障阿尔茨海默病医疗之旅-欧洲最佳实践兴起报告（英文版）

With the arrival of disease-modifying therapies (DMTs), blood-based biomarkers (BBMs) and digital solutions, health systems across Europe face a pivotal opportunity to transform Alzheimer’s disease (AD) diagnosis and care. These innovations bring new hope but also highlight the urgent need for investment in healthcare systems to ensure that scientific progress translates into population-level benefit. Timely diagnosis, coordinated care, and equitable access are no longer aspirational goals; t